Compare Becton Dickinson and Co (BDX) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs ArcelorMittal SA — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while ArcelorMittal SA trades at $67.74 (market cap $50.59B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | MT | |
|---|---|---|
Market Cap | $41.51B | $50.59B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $71.65 |
52-Week Low | $135.49 | $30.39 |
Enterprise Value | $57.97B | $59.91B |
Dividend Yield | 2.79% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
ArcelorMittal (MT) trades at $65.92, down 0.24% today, with a bullish technical outlook and strong recent earnings beats. The stock shows robust fundamentals with a P/E of 17.26 and P/S of 0.81, supported by a net income margin of 4.71% and consistent dividend payments. Recent news highlights expansion initiatives and a strategic AI collaboration with AWS, driving positive sentiment amid a 41% six-month gain (Zacks Investment Research, 2026-06-23).
Outlook remains positive with analyst consensus at 50% buy ratings, though risks include cyclical steel demand and high capital expenditure. The stock's valuation appears reasonable, but investors should monitor global economic conditions and steel pricing trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
